BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

914 related articles for article (PubMed ID: 32376152)

  • 1. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
    Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
    J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly Efficient Ex Vivo Correction of COL7A1 through Ribonucleoprotein-Based CRISPR/Cas9 and Homology-Directed Repair to Treat Recessive Dystrophic Epidermolysis Bullosa.
    Berthault C; Gaucher S; Gouin O; Schmitt A; Chen M; Woodley D; Titeux M; Hovnanian A; Izmiryan A
    J Invest Dermatol; 2024 Jun; 144(6):1322-1333.e13. PubMed ID: 38043638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COL7A1 Editing via CRISPR/Cas9 in Recessive Dystrophic Epidermolysis Bullosa.
    Hainzl S; Peking P; Kocher T; Murauer EM; Larcher F; Del Rio M; Duarte B; Steiner M; Klausegger A; Bauer JW; Reichelt J; Koller U
    Mol Ther; 2017 Nov; 25(11):2573-2584. PubMed ID: 28800953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient Gene Reframing Therapy for Recessive Dystrophic Epidermolysis Bullosa with CRISPR/Cas9.
    Takashima S; Shinkuma S; Fujita Y; Nomura T; Ujiie H; Natsuga K; Iwata H; Nakamura H; Vorobyev A; Abe R; Shimizu H
    J Invest Dermatol; 2019 Aug; 139(8):1711-1721.e4. PubMed ID: 30831133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically corrected iPSCs as cell therapy for recessive dystrophic epidermolysis bullosa.
    Wenzel D; Bayerl J; Nyström A; Bruckner-Tuderman L; Meixner A; Penninger JM
    Sci Transl Med; 2014 Nov; 6(264):264ra165. PubMed ID: 25429058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model.
    Wu W; Lu Z; Li F; Wang W; Qian N; Duan J; Zhang Y; Wang F; Chen T
    Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1660-1665. PubMed ID: 28137859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically Relevant Correction of Recessive Dystrophic Epidermolysis Bullosa by Dual sgRNA CRISPR/Cas9-Mediated Gene Editing.
    Bonafont J; Mencía Á; García M; Torres R; Rodríguez S; Carretero M; Chacón-Solano E; Modamio-Høybjør S; Marinas L; León C; Escamez MJ; Hausser I; Del Río M; Murillas R; Larcher F
    Mol Ther; 2019 May; 27(5):986-998. PubMed ID: 30930113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing.
    Bonafont J; Mencía A; Chacón-Solano E; Srifa W; Vaidyanathan S; Romano R; Garcia M; Hervás-Salcedo R; Ugalde L; Duarte B; Porteus MH; Del Rio M; Larcher F; Murillas R
    Mol Ther; 2021 Jun; 29(6):2008-2018. PubMed ID: 33609734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa.
    Shinkuma S; Guo Z; Christiano AM
    Proc Natl Acad Sci U S A; 2016 May; 113(20):5676-81. PubMed ID: 27143720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs.
    Osborn MJ; Newby GA; McElroy AN; Knipping F; Nielsen SC; Riddle MJ; Xia L; Chen W; Eide CR; Webber BR; Wandall HH; Dabelsteen S; Blazar BR; Liu DR; Tolar J
    J Invest Dermatol; 2020 Feb; 140(2):338-347.e5. PubMed ID: 31437443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.
    Sebastiano V; Zhen HH; Haddad B; Bashkirova E; Melo SP; Wang P; Leung TL; Siprashvili Z; Tichy A; Li J; Ameen M; Hawkins J; Lee S; Li L; Schwertschkow A; Bauer G; Lisowski L; Kay MA; Kim SK; Lane AT; Wernig M; Oro AE
    Sci Transl Med; 2014 Nov; 6(264):264ra163. PubMed ID: 25429056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The development of induced pluripotent stem cell-derived mesenchymal stem/stromal cells from normal human and RDEB epidermal keratinocytes.
    Nakayama C; Fujita Y; Matsumura W; Ujiie I; Takashima S; Shinkuma S; Nomura T; Abe R; Shimizu H
    J Dermatol Sci; 2018 Sep; 91(3):301-310. PubMed ID: 29933899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa.
    Hong SA; Kim SE; Lee AY; Hwang GH; Kim JH; Iwata H; Kim SC; Bae S; Lee SE
    Mol Ther; 2022 Aug; 30(8):2664-2679. PubMed ID: 35690907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and characterization of induced pluripotent stem cell lines from two patients with recessive dystrophic epidermolysis Bullosa.
    Vincent C; Lefort N; Hamlin M; Banal C; Hovnanian A; Izmiryan A
    Stem Cell Res; 2023 Jun; 69():103104. PubMed ID: 37148821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.
    Rami A; Łaczmański Ł; Jacków-Nowicka J; Jacków J
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33383666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes.
    Latella MC; Cocchiarella F; De Rosa L; Turchiano G; Gonçalves MAFV; Larcher F; De Luca M; Recchia A
    J Invest Dermatol; 2017 Apr; 137(4):836-844. PubMed ID: 28027893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells.
    Jacków J; Guo Z; Hansen C; Abaci HE; Doucet YS; Shin JU; Hayashi R; DeLorenzo D; Kabata Y; Shinkuma S; Salas-Alanis JC; Christiano AM
    Proc Natl Acad Sci U S A; 2019 Dec; 116(52):26846-26852. PubMed ID: 31818947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa.
    Siprashvili Z; Nguyen NT; Gorell ES; Loutit K; Khuu P; Furukawa LK; Lorenz HP; Leung TH; Keene DR; Rieger KE; Khavari P; Lane AT; Tang JY; Marinkovich MP
    JAMA; 2016 Nov; 316(17):1808-1817. PubMed ID: 27802546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa.
    Tolar J; McGrath JA; Xia L; Riddle MJ; Lees CJ; Eide C; Keene DR; Liu L; Osborn MJ; Lund TC; Blazar BR; Wagner JE
    J Invest Dermatol; 2014 May; 134(5):1246-1254. PubMed ID: 24317394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Keratinocyte cell lines derived from severe generalized recessive epidermolysis bullosa patients carrying a highly recurrent COL7A1 homozygous mutation: models to assess cell and gene therapies in vitro and in vivo.
    Chamorro C; Almarza D; Duarte B; Llames SG; Murillas R; García M; Cigudosa JC; Espinosa-Hevia L; Escámez MJ; Mencía A; Meana A; García-Escudero R; Moro R; Conti CJ; Del Río M; Larcher F
    Exp Dermatol; 2013 Sep; 22(9):601-3. PubMed ID: 23947675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.